Treatment of diseases and conditions caused by increased vascular permeability

Abstract

The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

1 .- 15 . (canceled) 
     
     
         16 . A method for treating diseases and conditions caused by or exhibiting increased vascular permeability in a patient in need thereof comprising administering to the patient a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS). 
     
     
         17 . The method of  claim 16  wherein the disease or condition is selected from the group consisting of pulmonary edema; pulmonary fibrosis; acute respiratory distress syndrome; septic shock; hyperpermeability triggered by inflammation or ischemia in the heart, brain; insect bites; natural or synthetic chemical irritants; frostbite; toxins; infection by pathogens; immune reactions due to hypersensitivity; foreign bodies; stress; trauma; appendicitis; bursitis; colitis; cystitis; dermatitis; phlebitis; rhinitis; tendonitis; tonsillitis; vasculitis; and release of prostaglandins (E1, E2, F1α and F2α), histamine, serotonin, bradykinin, cytokine storms, and lipopolysaccharides. 
     
     
         18 . The method of  claim 16  wherein the ACCS formulated for topical administration. 
     
     
         19 . The method of  claim 16  wherein the ACCS is formulated for parenteral administration. 
     
     
         20 . The method of  claim 16  wherein the ACCS is formulated for enteral administration. 
     
     
         21 . The method of  claim 16  wherein the ACCS formulated for intranasal administration.